Studies on relapse of leprosy in multi bacillary patients, either on treatment or after cessation of treatment with sulphone therapy, have been carried out in several countries1 -7,9-11,14,16 with different results. The crude relapse rate ranged from 4·5 to 20% in patients on treatment1. 4 and from 4·8 to 45·5% in patients released from treatment2,4,6, 1 0 ,14, 16 and the risk of relapse from 4·5 to 6·3 per 100 patient years.3,7.1 0 ,1 1 In one study, the cumulative relapse probability varied from 10·6 to 62·4% according to the type of lepromatous leprosy and to the level of attendance for treatment by the patients.1 0 In a more recent study,S it was 18·9% , For the treatment of leprosy, dapsone monotherapy has been replaced by multidrug therapy but the efficacy of treatment is still assessed on the occurrence of relapse. Accurate knowledge on relapse in patients on dapsone mono therapy as well as those on multidrug therapy is still required to compare the efficacy of different schemes of treatment. The aim of this paper is to report the relapse rate, the risk of relapse, the cumulative relapse probability and the incubation time of relapse observed in a retrospective study of 145 patients detected in French Polynesia between 1946 and 1970, put on dapsone monotherapy and fo llowed-up for a median period of time of 18 years after bacteriological negativity. 2 
Materials and methods
Between 1946 and 1970, 295 new leprosy patients were detected in French Polynesia, of whom 145 were multibacillary, put on dapsone mono therapy, and correspond to the study population. Each year of the study, patients were withdrawn when they fulfilled one of the 3 fo llowing exclusion criteria: (i) they were declared 'off register' (according to the OMSLEP system);8 (ii) they did not remain on dapsone monotherapy; and (iii) they suffered a relapse (each relapsing patient was excluded the year fo llowing the relapse). Each patient entered into the study (starting date or year 0) when he became bacteriologically negative. The closing date of the study was 31 December 1988. For each patient, the trial time was the period of time elapsed between the year he entered into the study and either the year he was withdrawn or the last year of the study (1988) .
From 1946 to 1970 the diagnosis of leprosy was based on a clinical examination of the skin and large nerve trunks, supplemented by biological tests: the search for acid-fast bacilli in the nasal mucosa and the skin (earlobes and skin lesions), biopsy for histopathological examination and, since 1951, the lepromin intradermal reaction. For the purpose of this study patients were designated paucibacillary or multi bacillary retrospectively, according to the data in the medical records: a leprosy patient was considered as muItibacillary when acid-fast bacilli with a bacteriological index (BI) � 2 were fo und in at least one of the samples (bacteriological or pathological examination). A relapse was defined as the reappearance of acid-fast bacilli with BI � 2 in at least one sample, accompanied by clinical signs, in a multibacillary patient who had been negative for 3 years or more. The incubation time of the relapse was defined as the period of time between the moment the patient became bacteriologically negative and the moment the relapse was detected. In 1946, sulphone therapy was the basis of treatment, dapsone was introduced in 1948 and prescribed as a lifelong monotherapy for multi bacillary patients. Rifampicin began to be prescribed occasionally from 1970 onwards.
Data analysed in this study comes partly from the central register and partly from the medical records of the patients. They were anonymously computerized according to the OMSLEP system. Statistical analysis was by Student's t-test, Pearson's chi-square test and exploratory data analysis.
IS The cumulative relapse probability was established using lifetable methods.1 3 The 95% confidence limits of the cumulative relapse probability were calculated using Rothman's fo rmula. 12 negativity time (period of time required to achieve bacteriological negativity) ranged from 2 to 12 years (on average 4·72 years), it was significantly higher (t = 2,07, P < 0'05) in the 36 relapsing patients (5'3 years) than in the 95 nonrelapsing patients (4'5 years). The number of relapses was 36, thus giving a crude relapse rate of27·5%. Of the 131 patients, 55 (42%) were females, of the 36 relapsing patients, 14 (39%) were fe males. The earliest relapse was observed in a patient 4 years after reaching negativity and the latest one 26 years after. The incubation time of relapses ranged between 4 and 8· 5 years in 9 of the 36 relapsing patients
Ye ars after bacteriological negativation Figure I . Evolution of the risk of relapse with the passage of time in 131 multi bacillary patients on dapsone monotherapy fo llowed-up during 36 years after bacteriological negativity.
(25%), between 8·5 and 18·5 years in 18 (50%) and between 18·5 and 26 years in the last 9 (25%). The median incubation time was 13·5 years ±2·6 (95% confidence limit). The cumulative exposed population since year 0 to year 36 was 2585 patient years (Table I) ; thus, a number of 36 relapses gives an average risk of relapse of I· 39 per 100 patient years. In order to assess whether a variation was observed with the passage of time during the 36 years of the study, we calculated the risk of relapse on 6 six-year periods of time. It was 0· 13, 1'69, 2'53, 2'07 and 1·69 per 100 patient years during the first, second, third, fo urth and fifth periods, respectively, and 0 during the sixth and last one ( Figure I ). No significant difference was fo und between the 5 risks of relapse (p > 0,05). The cumulative relapse probability (Table 1, Figure 2 ), which takes into account the patients withdrawn each year of the study, reached 0·38 (±0·11) on year 31, the closing date (afterwards, the study population was less than 10 patients, the minimum number required for lifetable evaluation).
Discussion
The data we have reported were collected from routine activities and not from a pre designed trial; however, the study has the advantage of a long fo llow-up period. As in any long-term retrospective study, caution has to be taken for the interpretation of the findings. The level of attendance for treatment by the patients, especially in lifelong therapy, is very difficult to assess; in the current study, we did not try to establish a correlation between the relapse rate and the attendance of patients for treatment, although in the medical records attendance was noted. According to the sex, no significant difference (p > 0·05) was fo und between the distribution of the relapses in the relapsing patients group (36% of the relapsing patients were fe males) and that of the patients in the study population (42% of the patients were females).
A crude relapse rate of 27'5%, over a total period of 36 years is not a surprising finding. In a study conducted in Russia, Torsuev et al. 14 reported the occurrence of 45 cases of clinical and bacteriological relapse among 187 patients fo llowed-up for 18 years, that is a 24· 1 % crude relapse rate. It must be pointed out that the crude relapse rate gives a simple proportion and does not take into account the patients withdrawn from the study. The I· 39 per 100 patient years risk of relapse observed in our study is not very different from the 1·2% to 3·2% risk reported by other authors. 3,7 In fa ct, the use of the risk of relapse is limited by the assumption that the occurrence of relapse is constant and this indicator is not representative of the kinetic of the occurrence of relapse. The cumulative relapse probability is a much more valid indicator because: (i) it allows consideration of all the patients entering into the study, as a single cohort; (ii) it takes into account the withdrawn patients; and (iii) it gives a picture of the occurrence of relapse each year over the whole study period. In our study it was O' 38 ± 0' 11, indicating that roughly one-third to one-half of multibacillary patients put on dapsone monotherapy would relapse if still present 36 years after bacteriological negativity. Such a figure needs to be compared with results reported by other authors. By 1970, Quagliato et al. ID calculated the cumulative relapse probability (using the Iifetable method) in a cohort of 815 multibacillary patients fo llowed-up over 22 years. The cohort was divided into 6 groups according to the severity of disease and the treatment regularity of the patients and overall cumulative relapse probability was not given. Nevertheless; it is reasonable to assume that it might have been similar to that we have reported. In 1989, Kurz et al. reported a lower cumulative relapse probability (18,9%) in a cohort of 1886 patients, but the median fo llow-up period was 10 years only and the confidence limits were not given.s A last important point is the incubation time of the relapse. In the present study, it ranged from 4 to 26 years and was, on median, 13·5 years ± 2·6. As shown in Table 1 , 86% (3 1 /36) of the relapses occurred between the fo urth and the twentieth year after bacteriological negativity and the last relapse occurred 26 years after bacteriological negativity. The 13·5 years median incubation time was similar to that reported in a study performed in Guadeloupe, in which 69 % of the relapses occurred between the first and the twentieth year after negativity. 3 Quagliato et al. reported comparable figures and, because the incubation time could be of more than 10 years, he suggested that treatment and fo llow-up of multibacillary patients on dapsone monotherapy should be continued for life.l o 5 
Conclusion
The main conclusions of our study are that: (a) the cumulative relapse probability is the best indicator for evaluation of the efficacy of treatment of leprosy; and (b) the considerable occurrence of relapse in multibacillary patients on dapsone monotherapy re emphasizes the necessity for leprosy patients to be put on multidrug therapy as recommended by WHO. . 36 rechutes ont ete detectees entre ces 131 patients, dont la premiere 4 ans et la derniere 26 ans apres avoir atteint negativite bacteriologique. Le taux brut de rechute a ete de 27,5%, Ie risque de rechute de 1,39 par 100 annees-patient et la probabilite accumulee de rechute, ca1culee par la methode 'lifetable', avait atteint 0,38 ± II par l'annee 31 de l'etude. A partir de ces resultats, on peut bien supposer que, au moins en Polinesie fran9aise, erttre un tiers et la moitie des patients multibacillaires qui auraient suivi un traitement de monotherapie de dapsone auraient souffert une rechute s'ils etaient encore en vie 36 ans apres avoir atteint negativite bacteriologique. Tels resultats soulignent encore Ie besoin de traiter d'une therapie a drogues multiples aux patients de lepre suivant les recommendations de la OMS.
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Resumen Entre 1946 y 1970 se detectaron en la Polinesia francesa 295 nuevos casos de lepra, entre los cuales
